ProMIS Neurosciences Strengthens Board with Appointment of Slanix Paul Alex, Pharm.D., President and Portfolio Manager, Public Equity of Ally Bridge Group

Core Insights - ProMIS Neurosciences has appointed Slanix Paul Alex to its Board of Directors, enhancing its strategic vision and investor engagement as it advances its Alzheimer's program, PMN310 [1][2] - The company is approaching key inflection points with planned data readouts in Q2 2026 and Q4 2026 from its PRECISE-AD trial evaluating PMN310 [2] Company Overview - ProMIS Neurosciences is a clinical-stage biotechnology company focused on developing next-generation therapies for Alzheimer's disease and other neurodegenerative disorders [1][4] - The company utilizes its proprietary EpiSelect™ platform to discover therapeutic antibodies and vaccines targeting toxic oligomers associated with neurodegenerative diseases [4][8] Product Development - PMN310 is ProMIS's lead product candidate, a humanized monoclonal antibody designed to selectively target toxic oligomers while avoiding plaque, potentially reducing the risk of amyloid-related imaging abnormalities (ARIA) [6][7] - The PRECISE-AD trial is a Phase 1b clinical study aimed at evaluating the safety, tolerability, and pharmacokinetics of PMN310 in patients with Mild Cognitive Impairment and mild Alzheimer's disease [7] Investment and Leadership - Slanix Paul Alex, with extensive experience in healthcare investment, is expected to provide valuable insights as ProMIS approaches critical clinical milestones [2][3] - Ally Bridge Group, a significant shareholder, has been instrumental in supporting ProMIS's growth and investment strategy [2][3]